| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.27 | 2e-06 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.16 | 3e-06 |
| mRNA | WH-4-023 | GDSC1000 | pan-cancer | AAC | 0.23 | 3e-05 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | BMS-509744 | GDSC1000 | pan-cancer | AAC | 0.23 | 9e-05 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.21 | 0.0002 |
| mRNA | Dasatinib | GDSC1000 | pan-cancer | AAC | 0.2 | 0.0003 |
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | 0.13 | 0.0003 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.16 | 0.0007 |